Universitât Bern

Akzo Nobel N.v.

Intervet International B.v.

University of Bern

Joachim Frey

Michael A Kuzyk

Jan Burian

Julian C Thornton

Peter Kuhnert

Tracy A Thornton, Legal Representative

Martin Braun

Katja Stuber

Ruud Philip Antoon Maria Segers

Edy M Vilei

Johannes Franciscus Van Den Bosch

Keith Redhead

Andreas Walter Claudius Rohwer

Anders Johansson

Paola Pilo

Ruud Philip Segers

The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin ofthat represents the major cytotoxic activity of. This toxin confersits characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis byon standard blood-agar medium or in cell-free supernatants of liquid cultures.

[object Object]

A protein toxin namedexoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter of. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity againstinfections.

The present invention relates i.a. to vaccines for combatinginfection, to mycoplasmal L-&#x3b1;-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-&#x3b1;-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals vaccinated with said vaccines and animals vaccinated with whole cell vaccines or animals suffering from field infection.

Mycoplasma subunit vaccine

Disclosed is a newly identified and characterized type III secretion system in. The invention also encompasses the use of components of the novel secretion system in immunoprotection againstinfection, as well as other diagnostic and therapeutic uses thereof.

A novel protein toxin namedexoenzyme T (AexT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a novel Calcium (or other cation concentration) dependent promoter ofAlso disclosed are diagnostic, preventative, and therapeutic techniques, including the preparation of traditional, recombinant, and improved bacterin vaccines based on AexT for inducing immunity againstinfections.

A protein toxin namedexoenzyme T (AcxT), which belongs to the family of ADP-ribosylating toxins, is disclosed as is a Calcium (or other cation concentration) dependent promoter of. Also disclosed are diagnostic, preventive, and therapeutic techniques, including the preparation of bacterin vaccines based on AexT for inducing immunity againstinfections.

The present invention relates to live attenuated bacteria of the genus that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic test for the selective diagnosis of infections and to diagnostic tests discriminating between field strains and vaccine strains.

Actinobacillus pleuropneumoniae subunit vaccine

The present invention relates to live attenuated RTX-toxin producing bacteria of the family Pasteurellaceae, of which the attenuation is due to the fact that they produce RTX toxin in a non-activated form. The invention also relates to vaccines for the protection of mammals against infection with RTX-toxin producing bacteria of the family Pasteurellaceae, and to methods for the preparation of said live attenuated bacteria and vaccines.

Live attenuated RTX-producing bacteria of the family pasteurellaceae

The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagonostic tests for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strain and vaccine strains.

Growing community of inventors

Bern, Switzerland

Joachim Frey